ES2117272T3 - Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas. - Google Patents

Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.

Info

Publication number
ES2117272T3
ES2117272T3 ES94916352T ES94916352T ES2117272T3 ES 2117272 T3 ES2117272 T3 ES 2117272T3 ES 94916352 T ES94916352 T ES 94916352T ES 94916352 T ES94916352 T ES 94916352T ES 2117272 T3 ES2117272 T3 ES 2117272T3
Authority
ES
Spain
Prior art keywords
protein
peptide
antibody
pharmaceutical compositions
compositions including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916352T
Other languages
English (en)
Inventor
Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Babraham Institute
Original Assignee
The Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Babraham Institute filed Critical The Babraham Institute
Application granted granted Critical
Publication of ES2117272T3 publication Critical patent/ES2117272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LAS COMPOSICIONES FARMACEUTICAS PARA ADMINISTRACION ORAL COMPRENDEN UNA PROTEINA O PEPTIDO,UN ANTICUERPO QUE ESPECIFICO PARA LA PROTEINA Y UNA PLURALIDAD DE PERLAS POLIMERICAS. LAS COMPOSICIONES PERMITEN QUE PROTEINAS Y PEPTIDOS SEAN APROPIADAS PARA SU ADMINISTRACION ORAL.
ES94916352T 1993-06-03 1994-06-02 Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas. Expired - Lifetime ES2117272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2117272T3 true ES2117272T3 (es) 1998-08-01

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916352T Expired - Lifetime ES2117272T3 (es) 1993-06-03 1994-06-02 Composiciones farmaceuticas orales que comprenden una proteina o peptido, un anticuerpo y esferas polimericas.

Country Status (9)

Country Link
EP (1) EP0707473B1 (es)
AT (1) ATE164311T1 (es)
AU (1) AU6804394A (es)
DE (1) DE69409237T2 (es)
DK (1) DK0707473T3 (es)
ES (1) ES2117272T3 (es)
GB (1) GB9311454D0 (es)
WO (1) WO1994028879A1 (es)
ZA (1) ZA943920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1275380A1 (en) * 1997-01-30 2003-01-15 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
DK0531497T3 (da) * 1991-04-02 1998-03-23 Biotech Australia Pty Ltd Orale indgivelsessystemer til mikropartikler

Also Published As

Publication number Publication date
GB9311454D0 (en) 1993-07-21
DE69409237D1 (de) 1998-04-30
DE69409237T2 (de) 1998-10-29
ZA943920B (en) 1995-12-04
ATE164311T1 (de) 1998-04-15
WO1994028879A1 (en) 1994-12-22
EP0707473A1 (en) 1996-04-24
EP0707473B1 (en) 1998-03-25
DK0707473T3 (da) 1999-01-04
AU6804394A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
NO306342B1 (no) Syntetiske eksitatoriske aminosyrer, farmasöytisk formulering inneholdende slike aminosyrer samt mellomprodukt
FI954978L (fi) Modifioidut proteiini- ja peptidilääkeaineet
MX9206938A (es) Nuevos derivados peptidos, proceso para su preparacion y preparacion farmaceutica que comprende tales derivados.
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
MX9201141A (es) Ciclosporinas cristalinas, procedimiento para su produccion y composicion farmaceutica que las contiene.
NL300190I2 (nl) Farmaceutische formuleringen met darifenacine.
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
FI956310L (fi) Stabiloidut farmaseuttiset peptidikoostumukset
NO954146D0 (no) Belagte farmasöytiske preparater
TR199501669A1 (tr) Peptid ve proteinlerin aerosol formülasyonlari.
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
DK0776885T3 (da) Biaromatiske forbindelser indeholdende en adamantylgruppe i positionen ortho, farmaceutiske og kosmetiske præparater, der i
AR002982A1 (es) Benzonitrilos y benzofluoruros, un procedimiento para prepararlos, su empleo para preparar médicamentos, un médicamento hecho a base de estos compuestos, las preparaciónes farmacéuticas que los contienen y un procedimiento para obtener estas preparaciónes farmacéuticas.
FI954111A7 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset v almisteet
IT8125703A0 (it) Tri-peptidi, tetra-peptidi o penta-peptidi, loro preparazione e farmaci che li contengono.
FI954986L (fi) Uudet, suun kautta annettavat, syklosporiinia sisältävät farmaseuttiset valmisteet
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
FI961938A7 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset v almisteet
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
FI971427A7 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
BR9605046B1 (pt) compostos n-(pirimidinl)-benzenossulfonamida e preparação farmacêutica contendo as mesmas.
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
TR199600583A2 (tr) Farmasötik aktiviteye sahip -amino asitlerin tolere edilebilirliginin arttirilmasi.
PT915087E (pt) Compostos anelados de cinco aneis, susbtituidos por sulfonamida, sua utilizacao como medicamentos, bem como preparacoes farmaceuticas contendo os mesmos
KR900701300A (ko) 생물학적 활성 펩티드 및 특정음이온을 갖는 조성물 및 이것을 사용하는 방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707473

Country of ref document: ES